Clinical Trial Update: An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates adjuvant therapy with Moderna's personalized cancer vaccine mRNA-4157 in combination with pembrolizumab for high-risk melanoma. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• mRNA-4157

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING